zenocutuzumab
merus
['mrus', 'merus']
the data we presented today at #asco2022 highlighting #zeno as a potential new standard of care for patients with nrg1+ cancer, for which there are currently no approved targeted therapies #personalizedmedicine #closeinoncancer $mrus 
Clinical-stage oncology company developing Biclonics® bispecific antibody therapeutics. Please see our Community Guidelines: https://t.co/qN9crK04bE